FOLH1 and cancer: Many patients with advanced cancer become unresponsive to ADTs, referred to as having metastatic castration-resistant prostate cancer (mCRPC) which has shown positive treatment response with lutetium-177 (177Lu)-prostate-specific membrane antigen (PSMA)-617 [6].